Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.

Gunawardhana L, Becker MA, Whelton A, Hunt B, Castillo M, Saag K.

Arthritis Res Ther. 2018 May 30;20(1):99. doi: 10.1186/s13075-018-1593-0.

2.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, Weroha SJ, Jen J, Sarkaria JN, Galanis E.

J Natl Cancer Inst. 2018 May 16. doi: 10.1093/jnci/djy033. [Epub ahead of print]

PMID:
29788332
3.

The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: A Review and Meta-Analysis.

Becker MAJ, Cornel JH, van de Ven PM, van Rossum AC, Allaart CP, Germans T.

JACC Cardiovasc Imaging. 2018 Apr 13. pii: S1936-878X(18)30279-1. doi: 10.1016/j.jcmg.2018.03.006. [Epub ahead of print]

PMID:
29680351
4.

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.

White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators.

N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12.

PMID:
29527974
5.

Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease.

de Bruyn JR, Becker MA, Steenkamer J, Wildenberg ME, Meijer SL, Buskens CJ, Bemelman WA, Löwenberg M, Ponsioen CY, van den Brink GR, D'Haens GR.

PLoS One. 2018 Jan 24;13(1):e0190999. doi: 10.1371/journal.pone.0190999. eCollection 2018.

6.

Bright triplet excitons in caesium lead halide perovskites.

Becker MA, Vaxenburg R, Nedelcu G, Sercel PC, Shabaev A, Mehl MJ, Michopoulos JG, Lambrakos SG, Bernstein N, Lyons JL, Stöferle T, Mahrt RF, Kovalenko MV, Norris DJ, Rainò G, Efros AL.

Nature. 2018 Jan 10;553(7687):189-193. doi: 10.1038/nature25147.

PMID:
29323292
7.

Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts.

Butler KA, Hou X, Becker MA, Zanfagnin V, Enderica-Gonzalez S, Visscher D, Kalli KR, Tienchaianada P, Haluska P, Weroha SJ.

Neoplasia. 2017 Aug;19(8):628-636. doi: 10.1016/j.neo.2017.04.007. Epub 2017 Jun 26.

8.

Summary of the 2015 Purine and Pyrimidine Society/Purine Metabolic Patients Association H. Anne Simmonds Memorial Lecture.

Becker MA.

Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):502-506. No abstract available.

PMID:
27906633
9.

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.

Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.

10.

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.

Becker MA, Hou X, Tienchaianada P, Haines BB, Harrington SC, Weroha SJ, Sathyanarayanan S, Haluska P.

BMC Cancer. 2016 Oct 20;16(1):814.

11.

Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).

Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA.

Arthritis Rheumatol. 2017 Jan;69(1):203-212. doi: 10.1002/art.39840.

12.

Risk of Early Rehospitalization for Non-Behavioral Health Conditions Among Adult Medicaid Beneficiaries with Severe Mental Illness or Substance Use Disorders.

Becker MA, Boaz TL, Andel R, Hafner S.

J Behav Health Serv Res. 2017 Jan;44(1):113-121. doi: 10.1007/s11414-016-9516-9.

PMID:
27270399
13.

Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer.

Becker MA, Ibrahim YH, Oh AS, Fagan DH, Byron SA, Sarver AL, Lee AV, Shaw LM, Fan C, Perou CM, Yee D.

PLoS One. 2016 Mar 18;11(3):e0150564. doi: 10.1371/journal.pone.0150564. eCollection 2016.

14.

Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment.

Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L.

Arthritis Rheumatol. 2016 Aug;68(8):2035-43. doi: 10.1002/art.39654.

15.

The Art and Science of Learning, Teaching, and Delivering Feedback in Psychosomatic Medicine.

Lokko HN, Gatchel JR, Becker MA, Stern TA.

Psychosomatics. 2016 Jan-Feb;57(1):31-40. doi: 10.1016/j.psym.2015.09.006. Epub 2015 Sep 30. Review.

PMID:
26683348
16.

Rehospitalization risk factors for psychiatric treatment among elderly Medicaid beneficiaries following hospitalization for a physical health condition.

Boaz TL, Becker MA, Andel R, McCutchan N.

Aging Ment Health. 2017 Mar;21(3):297-303. doi: 10.1080/13607863.2015.1104532. Epub 2015 Nov 2.

PMID:
26523783
17.

Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease.

Perez-Ruiz F, Becker MA.

Curr Med Res Opin. 2015;31 Suppl 2:9-14. doi: 10.1185/03007995.2015.1087980. Review.

PMID:
26414731
18.

An open-label, 6-month study of allopurinol safety in gout: The LASSO study.

Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, Baumgartner S.

Semin Arthritis Rheum. 2015 Oct;45(2):174-83. doi: 10.1016/j.semarthrit.2015.05.005. Epub 2015 May 21.

19.

Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.

Glaser G, Weroha SJ, Becker MA, Hou X, Enderica-Gonzalez S, Harrington SC, Haluska P.

PLoS One. 2015 May 11;10(5):e0126867. doi: 10.1371/journal.pone.0126867. eCollection 2015.

20.

Differences between winter oilseed rape (Brassica napus L.) cultivars in nitrogen starvation-induced leaf senescence are governed by leaf-inherent rather than root-derived signals.

Koeslin-Findeklee F, Becker MA, van der Graaff E, Roitsch T, Horst WJ.

J Exp Bot. 2015 Jul;66(13):3669-81. doi: 10.1093/jxb/erv170. Epub 2015 May 4.

21.

Transcriptomic analysis of nitrogen starvation- and cultivar-specific leaf senescence in winter oilseed rape (Brassica napus L.).

Koeslin-Findeklee F, Rizi VS, Becker MA, Parra-Londono S, Arif M, Balazadeh S, Mueller-Roeber B, Kunze R, Horst WJ.

Plant Sci. 2015 Apr;233:174-185. doi: 10.1016/j.plantsci.2014.11.018. Epub 2015 Jan 22.

PMID:
25711825
22.

A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.

Becker MA, Haluska P Jr, Bale LK, Oxvig C, Conover CA.

Mol Cancer Ther. 2015 Apr;14(4):973-81. doi: 10.1158/1535-7163.MCT-14-0880. Epub 2015 Feb 18.

23.

Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.

Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA.

J Clin Rheumatol. 2014 Dec;20(8):427-32. doi: 10.1097/RHU.0000000000000200. Review.

24.

Urate transporters: transforming the face of hyperuricemia and gout.

Becker MA, Simkin PA, Sorensen LB.

J Rheumatol. 2014 Oct;41(10):1910-2. doi: 10.3899/jrheum.141019. Epub 2014 Sep 1. No abstract available.

PMID:
25179848
25.

How Does a SILAR CdSe Film Grow? Tuning the Deposition Steps to Suppress Interfacial Charge Recombination in Solar Cells.

Becker MA, Radich JG, Bunker BA, Kamat PV.

J Phys Chem Lett. 2014 May 1;5(9):1575-82. doi: 10.1021/jz500481v. Epub 2014 Apr 17.

PMID:
26270098
26.

Long-term management of gout: nonpharmacologic and pharmacologic therapies.

Chaichian Y, Chohan S, Becker MA.

Rheum Dis Clin North Am. 2014 May;40(2):357-74. doi: 10.1016/j.rdc.2014.01.012. Epub 2014 Feb 20. Review.

PMID:
24703352
27.

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.

Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA.

Arthritis Res Ther. 2014 Mar 4;16(2):R60. doi: 10.1186/ar4497.

28.

A revised estimate of the burden of illness of gout.

Wertheimer A, Morlock R, Becker MA.

Curr Ther Res Clin Exp. 2013 Dec;75:1-4. doi: 10.1016/j.curtheres.2013.04.003.

29.

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P.

Clin Cancer Res. 2014 Mar 1;20(5):1288-97. doi: 10.1158/1078-0432.CCR-13-2611. Epub 2014 Jan 7.

30.

Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.

Scott CL, Becker MA, Haluska P, Samimi G.

Front Oncol. 2013 Dec 4;3:295. doi: 10.3389/fonc.2013.00295. Review.

31.

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.

Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA.

Arthritis Res Ther. 2013 Sep 26;15(5):R137. doi: 10.1186/ar4318.

32.

Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.

Becker MA, Farzan T, Harrington SC, Krempski JW, Weroha SJ, Hou X, Kalli KR, Wong TW, Haluska P.

Mol Cancer Ther. 2013 Dec;12(12):2909-16. doi: 10.1158/1535-7163.MCT-13-0547. Epub 2013 Oct 15.

33.

Risk factors for early readmission to acute care for persons with schizophrenia taking antipsychotic medications.

Boaz TL, Becker MA, Andel R, Van Dorn RA, Choi J, Sikirica M.

Psychiatr Serv. 2013 Dec 1;64(12):1225-9. doi: 10.1176/appi.ps.003382012.

PMID:
23945797
34.

Diabetes and gout: efficacy and safety of febuxostat and allopurinol.

Becker MA, MacDonald PA, Hunt BJ, Jackson RL.

Diabetes Obes Metab. 2013 Nov;15(11):1049-55. doi: 10.1111/dom.12135. Epub 2013 Jun 12.

35.

Long-term safety of pegloticase in chronic gout refractory to conventional treatment.

Becker MA, Baraf HS, Yood RA, Dillon A, Vázquez-Mellado J, Ottery FD, Khanna D, Sundy JS.

Ann Rheum Dis. 2013 Sep 1;72(9):1469-74. doi: 10.1136/annrheumdis-2012-201795. Epub 2012 Nov 10.

36.

Predictors of emergency commitment for nursing home residents: the role of resident and facility characteristics.

Becker MA, Boaz TL, DeMuth A, Andel R.

Int J Geriatr Psychiatry. 2012 Oct;27(10):1028-35.

PMID:
23115781
37.

Ser médico ...as a physician and professor at the University of Chicago.

Becker MA.

Rev Clin Esp. 2012 Mar;212(3):151-4. No abstract available.

PMID:
22532983
38.

The role of race and ethnicity in predicting length of hospice care among older adults.

Park NS, Carrion IV, Lee BS, Dobbs D, Shin HJ, Becker MA.

J Palliat Med. 2012 Feb;15(2):149-53. doi: 10.1089/jpm.2011.0220. Epub 2012 Feb 7.

PMID:
22313431
39.

IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.

Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, Carboni JM, Gottardis MM, Haluska P.

Clin Cancer Res. 2012 Mar 15;18(6):1808-17. doi: 10.1158/1078-0432.CCR-11-1806. Epub 2012 Jan 27.

40.

Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.

Becker MA, MacDonald PA, Hunt B, Gunawardhana L.

Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1011-7. doi: 10.1080/15257770.2011.603715.

PMID:
22132950
41.

Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.

Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL.

Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680.

42.

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA.

JAMA. 2011 Aug 17;306(7):711-20. doi: 10.1001/jama.2011.1169.

PMID:
21846852
43.

Do Latino and non-Latino White Medicaid-enrolled adults differ in utilization of evidence-based treatment for major depressive disorder?

Becker MA, Martinez-Tyson D, DiGennaro J, Ochshorn E.

J Immigr Minor Health. 2011 Dec;13(6):1048-54. doi: 10.1007/s10903-011-9508-z.

PMID:
21805165
44.

Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials.

Taylor WJ, Singh JA, Saag KG, Dalbeth N, MacDonald PA, Edwards NL, Simon LS, Stamp LK, Neogi T, Gaffo AL, Khanna PP, Becker MA, Schumacher HR Jr.

J Rheumatol. 2011 Jul;38(7):1467-70. doi: 10.3899/jrheum.110274.

PMID:
21724718
45.

Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?

Stamp LK, Khanna PP, Dalbeth N, Boers M, Maksymowych WP, Schumacher HR Jr, Becker MA, MacDonald PA, Edwards NL, Singh JA, Simon LS, McQueen FM, Neogi T, Gaffo AL, Strand V, Taylor WJ.

J Rheumatol. 2011 Jul;38(7):1462-6. doi: 10.3899/jrheum.110273.

46.

Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities.

Dalbeth N, McQueen FM, Singh JA, MacDonald PA, Edwards NL, Schumacher HR Jr, Simon LS, Stamp LK, Neogi T, Gaffo AL, Khanna PP, Becker MA, Taylor WJ.

J Rheumatol. 2011 Jul;38(7):1458-61. doi: 10.3899/jrheum.110272.

47.

Patient-reported outcomes in chronic gout: a report from OMERACT 10.

Singh JA, Taylor WJ, Simon LS, Khanna PP, Stamp LK, McQueen FM, Neogi T, Gaffo AL, Becker MA, MacDonald PA, Dabbous O, Strand V, Dalbeth ND, Aletaha D, Edwards NL, Schumacher HR Jr.

J Rheumatol. 2011 Jul;38(7):1452-7. doi: 10.3899/jrheum.110271.

48.

Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.

Van Dorn RA, Andel R, Boaz TL, Desmarais SL, Chandler K, Becker MA, Howe A.

J Clin Psychiatry. 2011 Apr;72(4):502-8. doi: 10.4088/JCP.10m06618.

PMID:
21527125
49.

The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells.

Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D.

Mol Endocrinol. 2011 Mar;25(3):516-28. doi: 10.1210/me.2010-0373. Epub 2011 Feb 3.

50.

Predictors of preventable nursing home hospitalizations: the role of mental disorders and dementia.

Becker MA, Boaz TL, Andel R, Gum AM, Papadopoulos AS.

Am J Geriatr Psychiatry. 2010 Jun;18(6):475-82. doi: 10.1097/JGP.0b013e3181b2145a.

PMID:
21217558

Supplemental Content

Loading ...
Support Center